9.70
-0.23(-2.32%)
Currency In USD
Previous Close | 9.93 |
Open | 9.69 |
Day High | 10.02 |
Day Low | 9.47 |
52-Week High | 23.4 |
52-Week Low | 3.52 |
Volume | 1.12M |
Average Volume | 2.64M |
Market Cap | 443.37M |
PE | -10.21 |
EPS | -0.95 |
Moving Average 50 Days | 10.83 |
Moving Average 200 Days | 13.56 |
Change | -0.23 |
If you invested $1000 in Capricor Therapeutics, Inc. (CAPR) 10 years ago, it would be worth $195.17 as of July 02, 2025 at a share price of $9.7. Whereas If you bought $1000 worth of Capricor Therapeutics, Inc. (CAPR) shares 5 years ago, it would be worth $2,113.29 as of July 02, 2025 at a share price of $9.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Jun 24, 2025 1:00 PM GMT
FDA has indicated that an Advisory Committee meeting is not required at this timeIn-person late-cycle review meeting scheduled for mid-July Biologics License Application (BLA) remains under Priority Review with PDUFA target action date of August 31,
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Jun 20, 2025 1:25 PM GMT
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel’s long-term safety profile remains favorableResults presented at PPMD’s 2025 Annual
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
GlobeNewswire Inc.
Jun 17, 2025 1:00 PM GMT
U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the August 31, 2025, PDUFA date for Deramiocel in Duchenne Muscul